Gulf Medical University (GMU), one of the top 50 medical educational institutes in the region, announced the launch of two new colleges and new programs as part of its planned educational strategy.
Dr. Thumbay Moideen, Founder and President of Thumbay Group has approved a budget of AED1 billion to expand and transform the Thumbay Medicity into a comprehensive educational and academic hub.
The new programs and colleges under Gulf Medical University were announced during a press conference hosted by the University Chancellor, Professor Hossam Hamdy, at GMU.
The latest development include the launch of two new colleges at the University, Nursing College and College of Health Care Management and Health Economics, which brings the total number of colleges to six.
GMU will also introduce new higher education programs in nursing during the academic 2018-19.
As part of this expansion, two new programs: Master’s degree in Public Health and another in Environmental Health and toxicology, came as a result of recently forged partnership between GMU and University of Arizona Mel and Enid Zuckerman College of Public Health (UA-MEZCOPH), USA.
The University had also signed several other memoranda of cooperation and understanding with a number of leading educational institutes, in an effort to enrich its students’ education.
The University is also implementing the latest technologies in teaching and training students across all majors, to ensure their work place readiness once they graduate.
One of the most prominent uses of technology in teaching is the Virtual Patient Learning (VPL), a simulation program that enables medical students to diagnose, treat and observe a patient’s progress. Based on Artificial Intelligence technology and developed by GMU and Swiss tech company Lifelike, secured top positions regionally and globally at the 2017 Reimagine Education Conference & Awards in the USA.
In terms of advancing healthcare in the UAE and globally, GMU had launched three facilities dedicated to medical research: Cancer Immunology and experimental oncology; Tumor genetic instability and immunogenicity; and biomarkers and Functional genomics.